Inhibition of CYP3A4 has been demonstrated in vitro (Budzinski et al 2000); however, two clinical studies have produced contradictory results (Chavez et al 2006).
Evidence from a recent in vitro study that investigated the effect of individual Ginkgo biloba 527
constituents in ginkgo suggests that several constituents found within ginkgo have
significant inhibitory activity; however, the principal components (terpene trilactones and flavonol glycosides) do not (von Moltke et al 2004). Ultimately, the clinical importance of these potential inhibitors will depend on their concentration within a commercial product and the extent of their bioavailability.
Was this article helpful?